Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
muscle relaxant
|
| gptkbp:approves |
children
adults |
| gptkbp:availableIn |
generic drug
|
| gptkbp:brand |
gptkb:Zanaflex
|
| gptkbp:chemicalFormula |
CYP1A2
C9H10ClN3O2S |
| gptkbp:commonName |
12 mg
6 mg 8 mg 2 mg 16 mg 4 mg 24 mg |
| gptkbp:contraindication |
liver disease
hypersensitivity |
| gptkbp:dosageForm |
tablet
capsule |
| https://www.w3.org/2000/01/rdf-schema#label |
Tizanidine
|
| gptkbp:isATypeOf |
63547-13-7
|
| gptkbp:isAvailableIn |
gptkb:Australia
gptkb:Canada gptkb:India gptkb:United_Kingdom gptkb:United_States |
| gptkbp:isRecognizedFor |
pregnant women
elderly patients nursing mothers patients with cardiovascular disorders patients with renal impairment |
| gptkbp:isRelatedTo |
brimonidine
clonidine dexmedetomidine guanfacine |
| gptkbp:issuedBy |
capsule
oral tablet |
| gptkbp:isUsedIn |
multiple sclerosis
muscle disorders spinal cord injury cerebral palsy stroke rehabilitation |
| gptkbp:lastProduced |
2000
|
| gptkbp:manufacturer |
gptkb:Acorda_Therapeutics
|
| gptkbp:operates_in |
M03BX02
|
| gptkbp:route |
oral
intravenous |
| gptkbp:sideEffect |
weakness
drowsiness dry mouth hypotension |
| gptkbp:triggerType |
alpha-2_adrenergic_agonist
|
| gptkbp:usedFor |
muscle spasticity
|